Shi Zhuangzhuang, Zhang Mingzhi
Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Lymphoma Diagnosis and Treatment Centre of Henan Province, Zhengzhou, China.
Clin Med Insights Oncol. 2021 Jun 17;15:11795549211024197. doi: 10.1177/11795549211024197. eCollection 2021.
Lymphoid neoplasms encompass a heterogeneous group of malignancies with a predilection for immunocompromised individuals, and the disease burden of lymphoid neoplasms has been rising globally over the last decade. At the same time, mounting studies delineated a crucial role of the gut microbiome in the aetiopathogenesis of various diseases. Orchestrated interactions between myriad microorganisms and the gastrointestinal mucosa establish a defensive barrier for a range of physiological processes, especially immunity and metabolism. These findings provide new perspectives to harness our knowledge of the gut microbiota for preclinical and clinical studies of lymphoma. Here, we review recent findings that support a role for the gut microbiota in the development of lymphoid neoplasms and pinpoint relevant molecular mechanisms. Accordingly, we propose the microbiota-gut-lymphoma axis as a promising target for clinical translation, including auxiliary diagnosis, novel prevention and treatment strategies, and predicting clinical outcomes and treatment-related adverse effects of the disease in the future. This review will reveal a fascinating avenue of research in the microbiota-mediated lymphoma field.
淋巴瘤涵盖了一组异质性的恶性肿瘤，好发于免疫功能低下的个体，在过去十年中，全球淋巴瘤的疾病负担一直在上升。与此同时，越来越多的研究表明肠道微生物群在各种疾病的病因发病机制中起着关键作用。众多微生物与胃肠道黏膜之间精心协调的相互作用为一系列生理过程建立了防御屏障，尤其是免疫和代谢。这些发现为利用我们对肠道微生物群的认识进行淋巴瘤的临床前和临床研究提供了新的视角。在这里，我们回顾了最近的研究结果，这些结果支持肠道微生物群在淋巴瘤发生发展中的作用，并确定了相关的分子机制。因此，我们提出微生物群-肠道-淋巴瘤轴作为一个有前景的临床转化靶点，包括辅助诊断、新的预防和治疗策略，以及预测该疾病未来的临床结果和治疗相关不良反应。这篇综述将揭示微生物群介导的淋巴瘤领域一个引人入胜的研究方向。
